Phase I Study of Combination Therapy with OBP-301, Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2033200223

Enrollment

Registered

2020-12-01

Start date

2021-01-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

OBP-301:Specified dose is administered transdermally. Atezolizumab :1200 mg IV infusion Q3W Bevacizumab:15 mg/kg IV infusion Q3W

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology Patients with cirrhosis require clinical confirmation of diagnosis based on the Clinical Practice Guidelines for Hepatocellular Carcinoma. - Disease that is not amenable to curative surgical and/or locoregional therapies - No prior systemic therapy (including non-approved and investigational agents) for HCC - ECOG Performance Status of 0 or 1 - Child-Pugh class A

Exclusion criteria

Exclusion criteria: - Fibrolamellar HCC, sarcomatoid HCC, or a mixed type of cholangiocellular carcinoma and HCC have been confirmed. - The patients who have history of hepatic encephalopathy - The patients with symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.

Design outcomes

Primary

Measure	Time frame
Safety Observation	—

Secondary

Measure	Time frame
Efficacy Tumor assessment, Observation	—

Contacts

Public ContactClinical trials information

Chugai Pharmaceutical Co., Ltd.

clinical-trials@chugai-pharm.co.jp+81-120-189-706

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026